** Erste Group Research cuts Austrian polymer and plastics
maker Semperit SMPV.VI to "hold" from "buy", saying the likely
EUR 50 mln impairment flagged earlier this week is further proof
of a challenging market environment urn:newsml:reuters.com:*:nEQ9ZCrcTa
** The impairment adds to near-term worries including
medical sector's post-pandemic woes, a surge in energy and raw
material costs, and possible Russian gas supply disruptions, it
says
** The broker cuts its estimates for 2022 EBITDA and net
result to profit of EUR 84.7 mln and loss of EUR 35.5 mln
respectively
** Erste says the Vienna-based firm could get a boost from
M&A deals as it plans to focus on the industrial sector in the
future, a possible trigger for the shares
** "However, given the current market situation, there is a
question mark hanging over the timing and shape of the planned
Sempermed segment sell-off," it adds
** Out of four analysts that cover Semperit, three rate the
stock "strong buy" or "buy" and one "hold"
($1 = 1.0025 euros)
(Reporting by Tristan Chabba)
((Tristan.chabba@thomsonreuters.com))